Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia

Kristian L Juul-Dam, MD, Charlotte G Nyvold, PhD, Hans B Ommen, MD PhD, Olafur G Jonsson, MD, Birgitte Lausen, MD, Kirsi Jahnukainen, MD PhD, Henrik Hasle, MD

Blood (2015) 126 (23): 3749.

https://doi.org/10.1182/blood.V126.23.3749.3749

Published: 2015

Journal Articles

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Miao-Chia Lo, Luke F. Peterson, Ming Yan, Xiuli Cong, Fulai Jin, Wei-Jong Shia, Shinobu Matsuura, Eun-Young Ahn, Yukiko Komeno, Minh Ly, Hans B. Ommen, I-Ming Chen, Peter Hokland, Cheryl L. Willman, Bing Ren, Dong-Er Zhang

Blood (2012) 120 (7): 1473–1484.

https://doi.org/10.1182/blood-2011-12-395335

Published: 2012

Includes: Supplemental data

Journal Articles

Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.

Miao-Chia Lo, Luke F. Peterson, Ming Yan, Eun-Young Ahn, Hans B. Ommen, I-Ming Chen, Peter Hokland, Cheryl L. Willman, Dong-Er Zhang

Blood (2008) 112 (11): 3336.

https://doi.org/10.1182/blood.V112.11.3336.3336

Published: 2008

Journal Articles

Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.

Hans B. Ommen, MD, Charlotte G. Nyvold, PhD, Karin Brændstrup, Bodil L. Andersen, Ingrid B. Ommen, MSc, Henrik Hasle, PhD, Peter Hokland, DMSc, Mette Ostergaard, PhD

Blood (2007) 110 (11): 3495.

https://doi.org/10.1182/blood.V110.11.3495.3495

Published: 2007

Journal Articles

Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).

Magdalena Plasilova, MD, PhD, Hans B. Ommen, MD, Jaroslav Jelinek, MD, PhD, Jean-Pierre Issa, MD, Elyn R. Riedel, Phd, Susan Mathew, PhD, Amy Chadburn, MD, Pengbo Zhou, PhD, Peter Hokland, MD, Malcolm A.S. Moore, PhD

Blood (2006) 108 (11): 2356.

https://doi.org/10.1182/blood.V108.11.2356.2356

Published: 2006

NARROW

qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.

Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.

Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia

Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML

Identification of the JAK/STAT Signaling Pathway as a Valid Therapeutic Target of T(8;21) Acute Myeloid Leukemia Using Combined Gene Expression and Promoter Occupancy Profiling.

Relapse Prediction in AML Patients in Complete Remission Using WT1 as a Molecular Marker: Development of a Mathematical Model To Predict Time from Molecular to Clinical Relapse and Define Optimal Sampling Intervals.

Loss of Heterozygosity (LOH) of the NUP98 Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only